ChAdOX1-nCoV-19

Interested in ChAdOX1-nCoV-19 ?   The ChAdOx1 nCoV-19 vaccine (AZD1222) consists of the replication-deficient simian adenovirus vector ChAdOx1. Oxford’s COVID-19 vaccine clinical trials began in April 2020. The main focus of the Phase I, II and III studies   Questions?   +447778936902 (WhatsApp) e-mail: head_office@nbscience.com